Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Pioneer Holding's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$95 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$166 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Shanghai Pioneer Holding's annualizedROC % for the quarter that ended in Dec. 2025 was 9.52%.
Shanghai Pioneer Holding's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 24.80%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Shanghai Pioneer Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 6.33%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Shanghai Pioneer Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pioneer Holding EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Shanghai Pioneer Holding's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shanghai Pioneer Holding's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$166 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pioneer Holding (HKSE:01345) has a EBIT of HK$166 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Pioneer Holding.
Is Shanghai Pioneer Holding's EBIT too high?
Shanghai Pioneer Holding's current EBIT is HK$166 Mil. Overall, Shanghai Pioneer Holding has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pioneer Holding's EBIT compare to competitors?
Shanghai Pioneer Holding's EBIT of HK$166 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Pioneer Holding. Shanghai Pioneer Holding's current EBIT is HK$166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pioneer Holding stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pioneer Holding (HKSE:01345) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.80, compared to a current price of HK$2.24 — trading 24.4% above its estimated fair value. The current EBIT is HK$166 Mil. Shanghai Pioneer Holding's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanghai Pioneer Holding (HKSE:01345), the current EBIT is HK$166 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pioneer Holding (HKSE:01345) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pioneer Holding stock appears to be overvalued.
The current stock price of HK$2.24 is trading 24.4% above its estimated GF Value™ of HK$1.80.
GuruFocus considers Shanghai Pioneer Holding to be Modestly Overvalued.
Key valuation signals for HKSE:01345:
EBIT: HK$166 Mil
GF Value™: HK$1.80 vs. price of HK$2.24 (24.4% above fair value)
No single metric tells the full story. See the HKSE:01345 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pioneer Holding Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the marketing, promotion, sales, and channel management service for imported pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, odontology, cardiology and wound care products. The majority of its revenue derives from the Sales of medical equipment and supplies. The group operates mainly in the People's Republic of China.
73GF Score
Get the complete analysis for HKSE:01345
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01345 has been successfully added to your 
